Component

Pancreatic islet beta cell

Pancreatic islet beta cell. Species, exposure and limitations are retained in each linked claim.

6 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Unlike in adult brain or islet alpha-cells in which GABA exerts hyperpolarizing effects, in islet beta-cells GABA produces membrane depolarization and calcium influx leading to the activation of PI3-kinase and Akt-dependent growth and survival pathways, this provides a potential mechanism underlying findings that GABA therapy preserves beta-cell mass and prevents the development of type 1 diabetes, remarkably in severely diabetic mice GABA restores beta-cell mass and reverses the disease, and GABA suppresses insulitis and systemic inflammatory cytokine production.

    Gamma-aminobutyric acid → Pancreatic islet beta cell source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/gaba-research/21709230.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "926bc916592c55cf6089bcb240ec5545e0ff3850e6d927bb82efacfc61841175", "start_char": 0, "end_char": 1117, "text_sha256": "926bc916592c55cf6089bcb240ec5545e0ff3850e6d927bb82efacfc61841175"}
    experimental_model
    Islet cell electrophysiology and signalling with GABA therapy in diabetes-prone and severely diabetic mice
    exposure
    GABA given therapeutically, with membrane potential, calcium influx and survival pathway readouts in beta cells
    limitations
    A mouse therapy study. Its electrophysiological claim about beta cells is stated as a contrast with alpha cells and brain rather than shown alongside a measured chloride gradient.
    nutrient_topic
    GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
    organism
    Mouse
    plain_language
    In the insulin-producing cell the same molecule does the opposite of what it does in the brain, and the cells survive better for it.
    primary_references
    [gb-p21709230] GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. (2011). https://pubmed.ncbi.nlm.nih.gov/21709230/ DOI: 10.1073/pnas.1102715108
    tissue_or_cell_type
    Pancreatic islet and immune system

    GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 430–441

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Islet cell electrophysiology and signalling with GABA therapy in diabetes-prone and severely diabetic mice · source_derived_draft · unverified_draft

    ### gb-gaba-depolarises-the-beta-cell Unlike in adult brain or islet alpha-cells in which GABA exerts hyperpolarizing effects, in islet beta-cells GABA produces membrane depolarization and calcium influx leading to the activation of PI3-kinase and Akt-dependent growth and survival pathways, this provides a potential mechanism underlying findings that GABA therapy preserves beta-cell mass and prevents the development of type 1 diabetes, remarkably in severely diabetic mice GABA restores beta-cell mass and reverses the disease, and GABA suppresses insulitis and systemic inflammatory cytokine production. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: In the insulin-producing cell the same molecule does the opposite of what it does in the brain, and the cells survive better for it. organism: Mouse tissue_or_cell_type: Pancreatic islet and immune system experimental_model: Islet cell electrophysiology and signalling with GABA therapy in diabetes-prone and severely diabetic mice limitations: A mouse therapy study. Its electrophysiological claim about beta cells is stated as a contrast with alpha cells and brain rather than shown alongside a measured chloride gradient. exposure: GABA given therapeutically, with membrane potential, calcium influx and survival pathway readouts in beta cells evidence_span: {"source_cache": "artifacts/gaba-research/21709230.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "926bc916592c55cf6089bcb240ec5545e0ff3850e6d927bb82efacfc61841175", "start_char": 0, "end_char": 1117, "text_sha256": "926bc916592c55cf6089bcb240ec5545e0ff3850e6d927bb82efacfc61841175"} [gb-p21709230] GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. (2011). https://pubmed.ncbi.nlm.nih.gov/21709230/ DOI: 10.1073/pnas.1102715108
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. A subset of GABA-A receptor subunits are expressed by CD4-positive T cells including the delta subunit that confers high affinity for GABA and sensitivity to alcohol, GABA at relatively low concentrations down-regulated effector T cell responses to beta cell antigens ex vivo and administration of GABA retarded the adoptive transfer of type 1 diabetes in NOD/scid mice, treatment with a low dose of GABA at 600 micrograms daily dramatically inhibited the development of proinflammatory T cell responses and disease progression in disease-prone mice that already had established autoimmunity, and GABA inhibited T cell receptor-mediated T cell cycle progression in vitro which may underlie the therapeutic effects.

    Gamma-aminobutyric acid → Type 1 diabetes source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/gaba-research/15470076.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e5523c02fc4571d5ab6c23776794b4b5cf025fb86cdba9acdc12011f3a6b2e09", "start_char": 0, "end_char": 1443, "text_sha256": "e5523c02fc4571d5ab6c23776794b4b5cf025fb86cdba9acdc12011f3a6b2e09"}
    experimental_model
    Subunit analysis with ex vivo antigen responses, adoptive transfer and treatment of disease-prone mice
    exposure
    GABA at low concentrations ex vivo, and 600 micrograms daily in mice with established autoimmunity
    limitations
    A mouse type 1 diabetes model. The cell cycle result offers a mechanism for the disease effect but is measured separately from it.
    nutrient_topic
    GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
    organism
    Mouse
    plain_language
    Low doses slowed the immune attack on the insulin-producing cells even after that attack had already started.
    primary_references
    [gb-p15470076] Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. (2004). https://pubmed.ncbi.nlm.nih.gov/15470076/ DOI: 10.4049/jimmunol.173.8.5298
    tissue_or_cell_type
    CD4 T cell and pancreatic islet

    GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 534–545

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Subunit analysis with ex vivo antigen responses, adoptive transfer and treatment of disease-prone mice · source_derived_draft · unverified_draft

    ### gb-gaba-slows-the-autoimmune-t-cell A subset of GABA-A receptor subunits are expressed by CD4-positive T cells including the delta subunit that confers high affinity for GABA and sensitivity to alcohol, GABA at relatively low concentrations down-regulated effector T cell responses to beta cell antigens ex vivo and administration of GABA retarded the adoptive transfer of type 1 diabetes in NOD/scid mice, treatment with a low dose of GABA at 600 micrograms daily dramatically inhibited the development of proinflammatory T cell responses and disease progression in disease-prone mice that already had established autoimmunity, and GABA inhibited T cell receptor-mediated T cell cycle progression in vitro which may underlie the therapeutic effects. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: Low doses slowed the immune attack on the insulin-producing cells even after that attack had already started. organism: Mouse tissue_or_cell_type: CD4 T cell and pancreatic islet experimental_model: Subunit analysis with ex vivo antigen responses, adoptive transfer and treatment of disease-prone mice limitations: A mouse type 1 diabetes model. The cell cycle result offers a mechanism for the disease effect but is measured separately from it. exposure: GABA at low concentrations ex vivo, and 600 micrograms daily in mice with established autoimmunity evidence_span: {"source_cache": "artifacts/gaba-research/15470076.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e5523c02fc4571d5ab6c23776794b4b5cf025fb86cdba9acdc12011f3a6b2e09", "start_char": 0, "end_char": 1443, "text_sha256": "e5523c02fc4571d5ab6c23776794b4b5cf025fb86cdba9acdc12011f3a6b2e09"} [gb-p15470076] Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. (2004). https://pubmed.ncbi.nlm.nih.gov/15470076/ DOI: 10.4049/jimmunol.173.8.5298
    Complete structured claim and evidence

  2. GABA was identified as an inducer of alpha-to-beta-like cell conversion in vivo, this conversion induces alpha cell replacement mechanisms through the mobilization of duct-lining precursor cells that adopt an alpha cell identity prior to being converted into beta-like cells solely upon sustained GABA exposure, these neo-generated beta-like cells are functional and can repeatedly reverse chemically induced diabetes in vivo, and similarly the treatment of transplanted human islets with GABA results in a loss of alpha cells and a concomitant increase in beta-like cell counts suggestive of alpha-to-beta-like cell conversion processes also in humans.

    Gamma-aminobutyric acid → Conversion of alpha cells into beta-like cells source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/gaba-research/27916274.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "4be6f165f91fed2e5ce13c111ae778fef006821e139b2702a3833f5924a4fffd", "start_char": 0, "end_char": 1087, "text_sha256": "4be6f165f91fed2e5ce13c111ae778fef006821e139b2702a3833f5924a4fffd"}
    experimental_model
    Lineage tracing and functional testing in mice with sustained GABA exposure, and treatment of transplanted human islets
    exposure
    Sustained long-term GABA administration in vivo, and GABA treatment of transplanted human islets
    limitations
    The human component is transplanted islets rather than people, and the cell counts are suggestive of conversion rather than a lineage trace in human tissue.
    nutrient_topic
    GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
    organism
    Mouse
    plain_language
    Given long enough, the molecule appeared to turn one islet cell type into the other, repeatedly reversing diabetes in mice.
    primary_references
    [gb-p27916274] Long-Term GABA Administration Induces Alpha Cell-Mediated Beta-like Cell Neogenesis. (2017). https://pubmed.ncbi.nlm.nih.gov/27916274/ DOI: 10.1016/j.cell.2016.11.002
    tissue_or_cell_type
    Pancreatic islet and duct

    GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 443–454

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Lineage tracing and functional testing in mice with sustained GABA exposure, and treatment of transplanted human islets · source_derived_draft · unverified_draft

    ### gb-sustained-gaba-makes-new-beta-like-cells GABA was identified as an inducer of alpha-to-beta-like cell conversion in vivo, this conversion induces alpha cell replacement mechanisms through the mobilization of duct-lining precursor cells that adopt an alpha cell identity prior to being converted into beta-like cells solely upon sustained GABA exposure, these neo-generated beta-like cells are functional and can repeatedly reverse chemically induced diabetes in vivo, and similarly the treatment of transplanted human islets with GABA results in a loss of alpha cells and a concomitant increase in beta-like cell counts suggestive of alpha-to-beta-like cell conversion processes also in humans. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: Given long enough, the molecule appeared to turn one islet cell type into the other, repeatedly reversing diabetes in mice. organism: Mouse tissue_or_cell_type: Pancreatic islet and duct experimental_model: Lineage tracing and functional testing in mice with sustained GABA exposure, and treatment of transplanted human islets limitations: The human component is transplanted islets rather than people, and the cell counts are suggestive of conversion rather than a lineage trace in human tissue. exposure: Sustained long-term GABA administration in vivo, and GABA treatment of transplanted human islets evidence_span: {"source_cache": "artifacts/gaba-research/27916274.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "4be6f165f91fed2e5ce13c111ae778fef006821e139b2702a3833f5924a4fffd", "start_char": 0, "end_char": 1087, "text_sha256": "4be6f165f91fed2e5ce13c111ae778fef006821e139b2702a3833f5924a4fffd"} [gb-p27916274] Long-Term GABA Administration Induces Alpha Cell-Mediated Beta-like Cell Neogenesis. (2017). https://pubmed.ncbi.nlm.nih.gov/27916274/ DOI: 10.1016/j.cell.2016.11.002
    Complete structured claim and evidence

  3. We studied 334 patients aged 10 to 20 years with type 1 diabetes, fasting C-peptide levels of more than 0.3 nanograms per millilitre and detectable serum GAD65 autoantibodies, randomly assigned within 3 months after diagnosis to four doses of GAD-alum, two doses followed by two doses of placebo, or four doses of placebo, the stimulated C-peptide level declined to a similar degree in all study groups and the primary outcome at 15 months did not differ significantly between the combined active-drug groups and the placebo group with P = 0.10, and the use of GAD-alum did not affect the insulin dose, glycated haemoglobin level or hypoglycaemia rate.

    Alum-formulated GAD65 antigen therapy → Stimulated serum C-peptide after a mixed-meal tolerance test source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/gaba-research/22296077.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "fc3bf9a083b3179c8573e993fb61f09412eca7890c3ccfb3ba5b8c0fb26acce8", "start_char": 0, "end_char": 1683, "text_sha256": "fc3bf9a083b3179c8573e993fb61f09412eca7890c3ccfb3ba5b8c0fb26acce8"}
    experimental_model
    Randomised placebo-controlled trial of an alum-formulated autoantigen in 334 patients within three months of diagnosis
    exposure
    Four doses of GAD-alum, two doses followed by placebo, or four doses of placebo, in patients aged 10 to 20 with detectable GAD65 autoantibodies
    limitations
    A properly powered randomised trial with stimulated C-peptide as the primary outcome. It tests the autoantigen as a therapy, not GABA.
    nutrient_topic
    GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
    organism
    Human
    plain_language
    Vaccinating against the enzyme the immune system attacks did not slow the loss of insulin production.
    primary_references
    [gb-p22296077] GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. (2012). https://pubmed.ncbi.nlm.nih.gov/22296077/ DOI: 10.1056/nejmoa1107096
    tissue_or_cell_type
    Pancreatic beta cell function

    GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 456–467

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomised placebo-controlled trial of an alum-formulated autoantigen in 334 patients within three months of diagnosis · source_derived_draft · unverified_draft

    ### gb-targeting-the-autoantigen-did-not-work We studied 334 patients aged 10 to 20 years with type 1 diabetes, fasting C-peptide levels of more than 0.3 nanograms per millilitre and detectable serum GAD65 autoantibodies, randomly assigned within 3 months after diagnosis to four doses of GAD-alum, two doses followed by two doses of placebo, or four doses of placebo, the stimulated C-peptide level declined to a similar degree in all study groups and the primary outcome at 15 months did not differ significantly between the combined active-drug groups and the placebo group with P = 0.10, and the use of GAD-alum did not affect the insulin dose, glycated haemoglobin level or hypoglycaemia rate. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: Vaccinating against the enzyme the immune system attacks did not slow the loss of insulin production. organism: Human tissue_or_cell_type: Pancreatic beta cell function experimental_model: Randomised placebo-controlled trial of an alum-formulated autoantigen in 334 patients within three months of diagnosis limitations: A properly powered randomised trial with stimulated C-peptide as the primary outcome. It tests the autoantigen as a therapy, not GABA. exposure: Four doses of GAD-alum, two doses followed by placebo, or four doses of placebo, in patients aged 10 to 20 with detectable GAD65 autoantibodies evidence_span: {"source_cache": "artifacts/gaba-research/22296077.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "fc3bf9a083b3179c8573e993fb61f09412eca7890c3ccfb3ba5b8c0fb26acce8", "start_char": 0, "end_char": 1683, "text_sha256": "fc3bf9a083b3179c8573e993fb61f09412eca7890c3ccfb3ba5b8c0fb26acce8"} [gb-p22296077] GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. (2012). https://pubmed.ncbi.nlm.nih.gov/22296077/ DOI: 10.1056/nejmoa1107096
    Complete structured claim and evidence

  4. The inhibitory neurotransmitter GABA is present in the endocrine part of the pancreas at concentrations comparable to those encountered in the central nervous system and co-localizes with insulin in pancreatic beta cells, and we describe a mechanism whereby GABA co-secreted with insulin from beta cells may mediate part of the inhibitory action of glucose on glucagon secretion by activating GABA-A receptor chloride channels in alpha 2 cells, providing a model for feedback regulation of glucagon release which may be of significance for understanding the hypersecretion of glucagon frequently associated with diabetes.

    Gamma-aminobutyric acid → Glucagon secretion source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/gaba-research/2550826.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9062539804213a1ccf427b75c8f6d262b151e22464cd6b7c84640f222f7dea94", "start_char": 0, "end_char": 1225, "text_sha256": "9062539804213a1ccf427b75c8f6d262b151e22464cd6b7c84640f222f7dea94"}
    experimental_model
    Electrophysiology of pancreatic alpha 2 cells with glucose and GABA
    exposure
    GABA co-secreted with insulin from beta cells, acting on GABA-A receptor chloride channels in alpha 2 cells
    limitations
    An early electrophysiological model. It proposes that GABA mediates part of the effect of glucose rather than demonstrating the whole of it.
    nutrient_topic
    GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
    organism
    Guinea pig and rat
    plain_language
    The cells that release insulin release GABA with it, and that is part of how a meal switches off the opposing hormone.
    primary_references
    [gb-p2550826] Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. (1989). https://pubmed.ncbi.nlm.nih.gov/2550826/ DOI: 10.1038/341233a0
    tissue_or_cell_type
    Pancreatic islet

    GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 404–415

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Electrophysiology of pancreatic alpha 2 cells with glucose and GABA · source_derived_draft · unverified_draft

    ### gb-the-islet-signals-with-gaba The inhibitory neurotransmitter GABA is present in the endocrine part of the pancreas at concentrations comparable to those encountered in the central nervous system and co-localizes with insulin in pancreatic beta cells, and we describe a mechanism whereby GABA co-secreted with insulin from beta cells may mediate part of the inhibitory action of glucose on glucagon secretion by activating GABA-A receptor chloride channels in alpha 2 cells, providing a model for feedback regulation of glucagon release which may be of significance for understanding the hypersecretion of glucagon frequently associated with diabetes. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: The cells that release insulin release GABA with it, and that is part of how a meal switches off the opposing hormone. organism: Guinea pig and rat tissue_or_cell_type: Pancreatic islet experimental_model: Electrophysiology of pancreatic alpha 2 cells with glucose and GABA limitations: An early electrophysiological model. It proposes that GABA mediates part of the effect of glucose rather than demonstrating the whole of it. exposure: GABA co-secreted with insulin from beta cells, acting on GABA-A receptor chloride channels in alpha 2 cells evidence_span: {"source_cache": "artifacts/gaba-research/2550826.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9062539804213a1ccf427b75c8f6d262b151e22464cd6b7c84640f222f7dea94", "start_char": 0, "end_char": 1225, "text_sha256": "9062539804213a1ccf427b75c8f6d262b151e22464cd6b7c84640f222f7dea94"} [gb-p2550826] Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. (1989). https://pubmed.ncbi.nlm.nih.gov/2550826/ DOI: 10.1038/341233a0
    Complete structured claim and evidence

  5. Rat beta-cells release GABA by calcium-dependent exocytosis of synaptic-like microvesicles and the GABA thus released can diffuse over sufficient distances within the islet interstitium to activate GABA-A receptors in neighboring cells, confocal immunocytochemistry revealed the presence of GABA-A receptors in glucagon-secreting alpha-cells but not in beta- and delta-cells with transcripts of alpha1, alpha4 and beta1-3 subunits detected in purified alpha-cells but not in beta-cells, the antagonist SR95531 increased glucagon secretion at 1 millimolar glucose twofold and completely abolished the inhibitory action of 20 millimolar glucose on glucagon release, and basal and glucose-stimulated secretion of insulin and somatostatin were unaffected.

    SR95531, a GABA-A receptor antagonist → Glucagon secretion source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/gaba-research/15047619.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1f64e75f4c5822ecc05331804e4d127c8b1702249327c4ed85fa07d96898d5b0", "start_char": 0, "end_char": 1478, "text_sha256": "1f64e75f4c5822ecc05331804e4d127c8b1702249327c4ed85fa07d96898d5b0"}
    experimental_model
    Confocal immunocytochemistry, transcript analysis, whole-cell voltage clamp and hormone secretion with a receptor antagonist
    exposure
    Endogenous GABA released from beta cells, with the GABA-A antagonist SR95531 and the calcium channel blocker isradipine
    limitations
    The antagonist experiment is what makes this causal for the endogenous signal. Receptor detection was by immunocytochemistry and transcripts in purified cells.
    nutrient_topic
    GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
    organism
    Rat
    plain_language
    Block the receptor and glucose stops switching off glucagon entirely, and the receptor is on the glucagon cell and not on the insulin cell.
    primary_references
    [gb-p15047619] Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells. (2004). https://pubmed.ncbi.nlm.nih.gov/15047619/ DOI: 10.2337/diabetes.53.4.1038
    tissue_or_cell_type
    Purified islet cells and intact islets

    GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 417–428

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Confocal immunocytochemistry, transcript analysis, whole-cell voltage clamp and hormone secretion with a receptor antagonist · source_derived_draft · unverified_draft

    ### gb-the-receptor-is-on-the-alpha-cell-only Rat beta-cells release GABA by calcium-dependent exocytosis of synaptic-like microvesicles and the GABA thus released can diffuse over sufficient distances within the islet interstitium to activate GABA-A receptors in neighboring cells, confocal immunocytochemistry revealed the presence of GABA-A receptors in glucagon-secreting alpha-cells but not in beta- and delta-cells with transcripts of alpha1, alpha4 and beta1-3 subunits detected in purified alpha-cells but not in beta-cells, the antagonist SR95531 increased glucagon secretion at 1 millimolar glucose twofold and completely abolished the inhibitory action of 20 millimolar glucose on glucagon release, and basal and glucose-stimulated secretion of insulin and somatostatin were unaffected. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: Block the receptor and glucose stops switching off glucagon entirely, and the receptor is on the glucagon cell and not on the insulin cell. organism: Rat tissue_or_cell_type: Purified islet cells and intact islets experimental_model: Confocal immunocytochemistry, transcript analysis, whole-cell voltage clamp and hormone secretion with a receptor antagonist limitations: The antagonist experiment is what makes this causal for the endogenous signal. Receptor detection was by immunocytochemistry and transcripts in purified cells. exposure: Endogenous GABA released from beta cells, with the GABA-A antagonist SR95531 and the calcium channel blocker isradipine evidence_span: {"source_cache": "artifacts/gaba-research/15047619.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1f64e75f4c5822ecc05331804e4d127c8b1702249327c4ed85fa07d96898d5b0", "start_char": 0, "end_char": 1478, "text_sha256": "1f64e75f4c5822ecc05331804e4d127c8b1702249327c4ed85fa07d96898d5b0"} [gb-p15047619] Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells. (2004). https://pubmed.ncbi.nlm.nih.gov/15047619/ DOI: 10.2337/diabetes.53.4.1038
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards